1. Home
  2. NEO

as of 02-06-2026 4:00pm EST

$11.42
+$0.15
+1.33%
Stocks Health Care Precision Instruments Nasdaq

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Founded: 2001 Country:
United States
United States
Employees: N/A City: FORT MYERS
Market Cap: 1.6B IPO Year: 1999
Target Price: $11.38 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.89 EPS Growth: N/A
52 Week Low/High: $4.72 - $14.73 Next Earning Date: 02-17-2026
Revenue: $709,162,000 Revenue Growth: 10.10%
Revenue Growth (this year): 10.86% Revenue Growth (next year): 9.70%
P/E Ratio: N/A Index: N/A
Free Cash Flow: -17049000.0 FCF Growth: N/A

AI-Powered NEO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 75.16%
75.16%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of NeoGenomics Inc. (NEO)

Stone Warren

Pres & Chief Operating Officer

Sell
NEO Jan 20, 2026

Avg Cost/Share

$12.50

Shares

22,128

Total Value

$276,681.87

Owned After

121,631

SEC Form 4

Share on Social Networks: